Remote patient monitoring has become more prevalent because of the pandemic. Baxter has won a nod from FDA for a technology that reinforces this trend.
The Deerfield, IL-based company won clearance for Homechoice Claria with the Sharesource Connectivity platform. The technology can be described as a home peritoneal dialysis
Baxter said Claria combines a simple user interface with the benefits of Sharesource, the only two-way remote patient management platform for patients on peritoneal dialysis in the U.S. Homechoice Claria is cleared for both adult and pediatric populations.
In Baxter’s most recent earnings call, Jose Almeida, the company’s chairman and CEO spoke about the state of the renal care industry and the impact of the COVID-19 on the space.
“Renal Care delivered mid-single-digit growth at constant currency rates for the quarter, driven by continued demand for our portfolio of peritoneal dialysis products,” Almeida said according to a Seeking Alpha transcript of the call. “Pandemic conditions continue to underscore the advantages of home-based PD treatment as well as Baxter's share source remote monitoring technology for both clinicians and patients.”
Homechoice Claria’s FDA clearance follows the recent finalization of the End-Stage Renal Disease (ESRD) Treatment Choices (ETC) payment model, which aims to significantly increase the number of new patients with kidney failure who receive home dialysis and/or organ transplants.
“Late in 3Q20, [Centers for Medicare & Medicaid Services] announced the finalization of the end-stage renal disease treatment choices payment model, a core component of the advancing American Kidney Health initiative,” Almeida said according to a Seeking Alpha transcript of the call. “This is a key step forward in increasing U.S. adoption of home-based dialysis care, and Baxter stands prepared to support patients and health care providers as the new model takes effect in 2021.”